ICICI Securities Limited
Nuvama Wealth Management Limited
SBI Capital Markets Limited
Suraksha Diagnostic Limited is a public limited company based in Kolkata, West Bengal, India, originally incorporated as Suraksha Diagnostic Private Limited in 2005. The company specializes in providing a comprehensive range of diagnostic services, including clinical laboratory tests, imaging services, and preventive health check-ups. Led by prominent figures such as Dr. Somnath Chatterjee, Ritu Mittal, and Satish Kumar Verma, Suraksha Diagnostic aims to leverage advanced technology and skilled professionals to deliver accurate and timely results. Positioned as a key player in the growing diagnostics sector, Suraksha Diagnostic is well-equipped to meet the increasing demand for healthcare services driven by rising health awareness. With plans to expand its service offerings and network, the company is poised for significant growth, contributing to the evolving healthcare landscape in India.
For the year/period ended (Rs. in Cr.)
FY24 | FY23 | FY22 | |
---|---|---|---|
Total Revenue | 218.7 | 190.1 | 223.2 |
Profit After Tax | 23.5 | 6.5 | 20.9 |
EPS | 4.43 | 1.22 | 3.91 |
OPM (%) | 32.04% | 23.10% | 28.08% |
PATM (%) | 10.57% | 3.37% | 9.25% |
For year/ period ended ( in Cr.)
Company Name | Market Cap (Cr.) | Price | P/BV | P/E | Sales (Cr.) FY23 |
Net Profits(Cr.) FY23 |
---|---|---|---|---|---|---|
Suraksha Diagnostic Ltd. | 846.25 | 441 | 13.10 | 99.55 | 222.3 | 23.5 |
Dr. Lal Pathlabs Ltd. | 25894.94 | 3098.25 | 10.5 | 52.8 | 2226.64 | 362.29 |
Metropolis Healthcare Ltd. | 11054.01 | 2156.15 | 8.13 | 69.19 | 1207.71 | 128.46 |
Thyrocare Technologies Ltd. | 5395.24 | 1018.5 | 6 | 44.13 | 571.88 | 69.49 |
Vijaya Diagnostic Centre Ltd. | 11876.28 | 1157.2 | 9.91 | 54.69 | 547.81 | 119.64 |
The company operates in healthcare diagnosis sector where many renowned and big companies are operating. At the upper Price of INR 441, the company is expected to list at P/E of 99.6 and P/B of 13.1. There are many peers which are cheaper than this company on P/E and P/B metrics. Hence, we maintain a “Neutral” stance due to relatively higher valuation
Never Miss IPO Investment